Candel Therapeutics company info

What does Candel Therapeutics do?
Candel Therapeutics (NASDAQ:CADL) specializes in the development of oncolytic viral therapies, a pioneering approach aimed at harnessing the power of viruses to selectively attack and destroy cancer cells while stimulating a potent, systemic immune response against the cancer. The company's innovative pipeline is focused on addressing a wide range of solid tumor types through robust clinical programs. With ongoing projects aimed at enhancing the efficacy and safety of cancer treatments, Candel Therapeutics is committed to improving patient outcomes and advancing the field of immuno-oncology. Their objective is to revolutionize cancer therapy by developing treatments that offer a better quality of life and survival rates for patients battling cancer.
Candel Therapeutics company media
Company Snapshot

Is Candel Therapeutics a public or private company?

key
Ownership
Public

How many people does Candel Therapeutics employ?

people
Employees
42

What sector is Candel Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Candel Therapeutics?

location pin
Head Office
Needham, United States

What year was Candel Therapeutics founded?

founded flag
Year Founded
2003
What does Candel Therapeutics specialise in?
/Gene Therapies /Oncology Treatments /Medical Research /Biotechnology Development /Clinical Trials /Immunotherapy Solutions

What are the products and/or services of Candel Therapeutics?

Overview of Candel Therapeutics offerings
Oncolytic Virus Therapy - Specializes in the development of novel oncolytic viral therapies for cancer patients, leveraging viruses to selectively kill cancer cells.
CAN-2409 (HSV-1) - An investigational gene-mediated cytotoxic immunotherapy using an engineered herpes simplex virus to treat high-grade gliomas, a type of brain cancer.
Neoantigen Technology - Works on personalized cancer vaccine technologies aiming to train the immune system to target specific mutations in cancer cells.
CAN-3110 (HSV-1) - A second-generation oncolytic virus engineered for increased selectivity and potency against cancer cells, particularly for glioblastoma.
Immuno-Oncology Pipeline - Involves the development of various immunotherapies designed to activate the patient’s immune system against cancer.
Clinical Trial Management - Offers comprehensive management of clinical trials for their cutting-edge cancer treatments, ensuring adherence to regulatory standards and patient safety.

Who is in the executive team of Candel Therapeutics?

Candel Therapeutics leadership team
  • Dr. Paul-Peter  Tak FMEDSCI, M.D., Ph.D.
    Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.
    President, CEO & Director
  • Dr. Estuardo  Aguilar-Cordova Inf., M.D., Ph.D.
    Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D.
    Founder & Director
  • Dr. Seshu  Tyagarajan Ph.D.
    Dr. Seshu Tyagarajan Ph.D.
    Chief Technical & Development Officer
  • Dr. Francesca  Barone M.D., Ph.D.
    Dr. Francesca Barone M.D., Ph.D.
    Chief Scientific Officer
  • Mr. Charles  Schoch
    Mr. Charles Schoch
    Interim CFO, VP of Finance & Corporate Controller
  • Ms. Ileen B. Winick
    Ms. Ileen B. Winick
    Chief People Officer
  • Ms. Susan  Stewart J.D., L.L.M.
    Ms. Susan Stewart J.D., L.L.M.
    Chief Regulatory Officer
  • Dr. William Garrett Nichols M.D., M.S.
    Dr. William Garrett Nichols M.D., M.S.
    Chief Medical Officer